A Phase 1 interventional study of Febuxostat XR 80 mg Capsule F1 and Febuxostat XR 80 mg Capsule F2 in Healthy Volunteers, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-01-19.
Sponsored by Takeda · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will assess the relative bioavailability, safety and tolerability following administration of 80 mg single oral doses of 4 febuxostat extended release (XR) formulations.
The drug being tested is this study is febuxostat XR. Four different formulations of febuxostat XR are being tested to see how the drug moves through the body. This study will look at safety and side effects in people who take febuxostat XR.
This cross-over study will enroll approximately 78 patients. Participants will be randomly assigned to 1of 4 sequences which will determine the order of the 4 treatments received:
Participants will take 1 dose on Day 1 with a washout period between each period.
This single-center trial will be conducted in the United States. The overall time to participate in this study is up to 80 days. Participants will make multiple visits to the clinic including a period of confinement, and will be contacted by telephone 30 days after last dose of study drug for a follow-up assessment.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Febuxostat XR 80 mg capsule Formulation 1 (F1), orally, once on Day 1 of Period 1 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 2 (F2), orally, once on Day 1 of Period 2 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 4 (F4), orally, once on Day 1 of Period 3 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 3 (F3), orally, once on Day 1 of Period 4 (C).
Drug: Febuxostat XR 80 mg Capsule F1 · Drug: Febuxostat XR 80 mg Capsule F2 · Drug: Febuxostat XR 80 mg Capsule F3 · Drug: Febuxostat XR 80 mg Capsule F4
Febuxostat XR 80 mg capsule F4, orally, once on Day 1 of Period 1 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1 orally, once on Day 1 of Period 2 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F3, orally, once on Day 1 of Period 3 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 4 (B).
Drug: Febuxostat XR 80 mg Capsule F1 · Drug: Febuxostat XR 80 mg Capsule F2 · Drug: Febuxostat XR 80 mg Capsule F3 · Drug: Febuxostat XR 80 mg Capsule F4
Febuxostat XR 80 mg capsule F3, orally, once on Day 1 of Period 1 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F4 orally, once on Day 1 of Period 2 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 3 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1, orally, once on Day 1 of Period 4 (A).
Drug: Febuxostat XR 80 mg Capsule F1 · Drug: Febuxostat XR 80 mg Capsule F2 · Drug: Febuxostat XR 80 mg Capsule F3 · Drug: Febuxostat XR 80 mg Capsule F4
Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 1 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F3 orally, once on Day 1 of Period 2 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1, orally, once on Day 1 of Period 3 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F4, orally, once on Day 1 of Period 4 (D).
Drug: Febuxostat XR 80 mg Capsule F1 · Drug: Febuxostat XR 80 mg Capsule F2 · Drug: Febuxostat XR 80 mg Capsule F3 · Drug: Febuxostat XR 80 mg Capsule F4
Febuxostat extended-release (XR) capsules formulation 1
Febuxostat XR capsules formulation 2
Febuxostat XR capsules formulation 3
Febuxostat XR capsules formulation 4
Mean Cmax: Maximum Observed Plasma Concentration for Febuxostat
Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Mean AUCt: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Febuxostat
AUCt is a measure of total plasma exposure to the drug from time 0 to time of the last quantifiable concentration.
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Mean AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Febuxostat
AUC∞ is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose
Participants took part in the study at 1 investigative site in the United States from 29 June 2015 to 01 October 2015.
| Milestone | Treatment Sequence ABDC | Treatment Sequence DACB | Treatment Sequence CDBA | Treatment Sequence BCAD |
|---|---|---|---|---|
| Started | 19 | 19 | 20 | 20 |
| Completed | 19 | 19 | 19 | 20 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Positive drug screen | 0 | 0 | 1 | 0 |
| Milestone | Treatment Sequence ABDC | Treatment Sequence DACB | Treatment Sequence CDBA | Treatment Sequence BCAD |
|---|---|---|---|---|
| Started | 19 | 19 | 19 | 20 |
| Completed | 19 | 18 | 19 | 20 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Positive drug screen | 0 | 1 | 0 | 0 |
| Milestone | Treatment Sequence ABDC | Treatment Sequence DACB | Treatment Sequence CDBA | Treatment Sequence BCAD |
|---|---|---|---|---|
| Started | 19 | 18 | 19 | 20 |
| Completed | 19 | 18 | 18 | 19 |
| Not completed | 0 | 0 | 1 | 1 |
| Withdrew: Positive drug screen | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
| Milestone | Treatment Sequence ABDC | Treatment Sequence DACB | Treatment Sequence CDBA | Treatment Sequence BCAD |
|---|---|---|---|---|
| Started | 19 | 18 | 18 | 19 |
| Completed | 19 | 18 | 18 | 19 |
| Not completed | 0 | 0 | 0 | 0 |
Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
| ng/mL | Regimen A: Febuxostat XR 80 mg Formulation 1 | Regimen B: Febuxostat XR 80 mg Formulation 2 | Regimen C: Febuxostat XR 80 mg Formulation 3 | Regimen D: Febuxostat XR 80 mg Formulation 4 |
|---|---|---|---|---|
| Mean Cmax: Maximum Observed Plasma Concentration for Febuxostat | 2027.1184 ± 1278.28368 | 1442.2267 ± 991.94583 | 1730.2468 ± 1013.56204 | 1809.3158 ± 1170.53245 |
AUCt is a measure of total plasma exposure to the drug from time 0 to time of the last quantifiable concentration.
| ng*hr/mL | Regimen A: Febuxostat XR 80 mg Formulation 1 | Regimen B: Febuxostat XR 80 mg Formulation 2 | Regimen C: Febuxostat XR 80 mg Formulation 3 | Regimen D: Febuxostat XR 80 mg Formulation 4 |
|---|---|---|---|---|
| Mean AUCt: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Febuxostat | 9395.6014 ± 3961.55203 | 7971.0624 ± 3291.36390 | 8652.7080 ± 3673.91666 | 8817.3600 ± 3429.94880 |
AUC∞ is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.
| ng*hr/mL | Regimen A: Febuxostat XR 80 mg Formulation 1 | Regimen B: Febuxostat XR 80 mg Formulation 2 | Regimen C: Febuxostat XR 80 mg Formulation 3 | Regimen D: Febuxostat XR 80 mg Formulation 4 |
|---|---|---|---|---|
| Mean AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Febuxostat | 9368.0744 ± 3944.01280 | 8278.6143 ± 3205.31556 | 8938.8765 ± 3746.60153 | 9102.3700 ± 3430.45699 |
Collected over From the first administration of study drug on Day 1 of Period 1 up to 30 days after the last dose of study drug or Early termination visit (approximately up to 95 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Regimen A: Febuxostat XR 80 mg Formulation 1 | — | 0/76 (0%) | 6/76 (7.9%) |
| Regimen B: Febuxostat XR 80 mg Formulation 2 | — | 1/76 (1.3%) | 9/76 (11.8%) |
| Regimen C: Febuxostat XR 80 mg Formulation 3 | — | 0/77 (0%) | 7/77 (9.1%) |
| Regimen D: Febuxostat XR 80 mg Formulation 4 | — | 0/76 (0%) | 7/76 (9.2%) |
| Event | Regimen A: Febuxostat XR 80 mg Formulation 1 | Regimen B: Febuxostat XR 80 mg Formulation 2 | Regimen C: Febuxostat XR 80 mg Formulation 3 | Regimen D: Febuxostat XR 80 mg Formulation 4 |
|---|---|---|---|---|
| Blood creatine phosphokinase increasedInvestigations | 0/76 | 1/76 | 0/77 | 0/76 |
| Event | Regimen A: Febuxostat XR 80 mg Formulation 1 | Regimen B: Febuxostat XR 80 mg Formulation 2 | Regimen C: Febuxostat XR 80 mg Formulation 3 | Regimen D: Febuxostat XR 80 mg Formulation 4 |
|---|---|---|---|---|
| HeadacheNervous system disorders | 1/76 | 2/76 | 1/77 | 3/76 |
| NasopharyngitisInfections and infestations | 0/76 | 2/76 | 0/77 | 0/76 |
| DiarrhoeaGastrointestinal disorders | 0/76 | 0/76 | 2/77 | 0/76 |
| NauseaGastrointestinal disorders | 1/76 | 0/76 | 0/77 | 1/76 |
| VomitingGastrointestinal disorders | 0/76 | 1/76 | 0/77 | 0/76 |
| Bacterial vaginosisInfections and infestations | 1/76 | 0/76 | 0/77 | 0/76 |
| Oral herpesInfections and infestations | 0/76 | 0/76 | 0/77 | 1/76 |
| TrichomoniasisInfections and infestations | 0/76 | 1/76 | 0/77 | 0/76 |
| ContusionInjury, poisoning and procedural complications | 0/76 | 0/76 | 0/77 | 1/76 |
| Back painMusculoskeletal and connective tissue disorders | 1/76 | 1/76 | 0/77 | 0/76 |
Safety Set included all participants who were enrolled and received at least 1 dose of study drug.
| Age, Continuous(years) | Treatment Sequence ABDC | Treatment Sequence DACB | Treatment Sequence CDBA | Treatment Sequence BCAD | Total |
|---|---|---|---|---|---|
| Mean | 31.7 ± 7.56 | 30.7 ± 6.51 | 34.0 ± 8.87 | 31.2 ± 7.78 | 31.9 ± 7.70 |
| Gender(Participants) | Treatment Sequence ABDC | Treatment Sequence DACB | Treatment Sequence CDBA | Treatment Sequence BCAD | Total |
|---|---|---|---|---|---|
| Female | 10 | 10 | 9 | 14 | 43 |
| Male | 9 | 9 | 11 | 6 | 35 |
| Race/Ethnicity, Customized(Participants) | Treatment Sequence ABDC | Treatment Sequence DACB | Treatment Sequence CDBA | Treatment Sequence BCAD | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 11 | 7 | 9 | 10 | 37 |
| Not Hispanic or Latino | 8 | 12 | 11 | 10 | 41 |
| Race/Ethnicity, Customized(Participants) | Treatment Sequence ABDC | Treatment Sequence DACB | Treatment Sequence CDBA | Treatment Sequence BCAD | Total |
|---|---|---|---|---|---|
| Asian | 0 | 0 | 0 | 1 | 1 |
| Black or African American | 4 | 7 | 6 | 6 | 23 |
| White | 15 | 11 | 14 | 13 | 53 |
| Multiracial | 0 | 1 | 0 | 0 | 1 |
| Region of Enrollment(Participants) | Treatment Sequence ABDC | Treatment Sequence DACB | Treatment Sequence CDBA | Treatment Sequence BCAD | Total |
|---|---|---|---|---|---|
| United States | 19 | 19 | 20 | 20 | 78 |
| Height(cm) | Treatment Sequence ABDC | Treatment Sequence DACB | Treatment Sequence CDBA | Treatment Sequence BCAD | Total |
|---|---|---|---|---|---|
| Mean | 167.6 ± 10.13 | 171.1 ± 11.75 | 167.5 ± 9.70 | 165.7 ± 6.67 | 167.9 ± 9.71 |
| Weight(kg) | Treatment Sequence ABDC | Treatment Sequence DACB | Treatment Sequence CDBA | Treatment Sequence BCAD | Total |
|---|---|---|---|---|---|
| Mean | 72.98 ± 12.685 | 79.05 ± 11.846 | 71.22 ± 12.350 | 69.72 ± 11.015 | 73.17 ± 12.273 |
| Body Mass Index (BMI)(kg/m^2) | Treatment Sequence ABDC | Treatment Sequence DACB | Treatment Sequence CDBA | Treatment Sequence BCAD | Total |
|---|---|---|---|---|---|
| Mean | 25.84 ± 2.663 | 26.98 ± 2.722 | 25.29 ± 3.168 | 25.28 ± 2.802 | 25.83 ± 2.878 |
5 further baseline measures are reported on the registry.
The record gives a start of Aug 2015, a primary completion of Sep 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Febuxostat